| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma |
| Completed | 1 | 84 | RoW | SHR3824, Henagliflozin, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes | 12/13 | 12/13 | | |
NCT02361138: The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers |
|
|
| Completed | 1 | 48 | RoW | SHR3824, Henagliflozin, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes | 05/14 | 05/14 | | |
NCT02353975: Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects |
|
|
| Completed | 1 | 12 | RoW | SHR3824 | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes | 07/14 | 09/14 | | |
NCT02346175: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients |
|
|
| Completed | 1 | 30 | RoW | SHR3824, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 09/14 | 12/14 | | |
NCT02354027: The Drug-drug Interaction of SHR3824 and Metformin |
|
|
| Completed | 1 | 12 | RoW | SHR3824 metformin, Henagliflozin metformin | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes | 11/14 | 01/15 | | |
NCT02500485: The Drug-drug Interaction of SHR3824 and SP2086 |
|
|
| Unknown status | 1 | 12 | RoW | SHR3824, SP2086, Henagliflozin, Retagliptin | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes | 07/15 | | | |
NCT02366351: The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients |
|
|
| Unknown status | 1 | 168 | RoW | SHR3824, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 01/16 | | | |
NCT02366377: The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients |
|
|
| Unknown status | 1 | 168 | NA | SHR3824, Placebo, Metformin | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 03/16 | | | |
NCT03159832: Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient |
|
|
| Unknown status | 1 | 24 | RoW | SHR3824 | Jiangsu HengRui Medicine Co., Ltd. | Renal Insufficiency,Type 2 Diabetes | 12/17 | 12/17 | | |
NCT03160014: Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment |
|
|
| Unknown status | 1 | 32 | RoW | SHR3824 | Jiangsu HengRui Medicine Co., Ltd. | Hepatic Impairment | 12/17 | 12/17 | | |
NCT03329118: Drug-drug Interaction Between Simvastatin and SHR3824 |
|
|
| Unknown status | 1 | 12 | NA | SHR3824, Simvastatin | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes | 12/17 | 12/17 | | |
NCT06083116: Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide |
|
|
| Completed | 1 | 12 | RoW | HydrochlorothiazideăHenagliflozin Proline | Jiangsu HengRui Medicine Co., Ltd. | Diabetes in Adults | 10/19 | 10/19 | | |
| Completed | 1 | 96 | RoW | ARM A, ARM B, ARM C, ARM D, ARM E, ARM F | Shandong Suncadia Medicine Co., Ltd. | Type 2 Diabetes | 04/23 | 04/23 | | |
ChiCTR2400079455: A multicenter, randomized, double-blind, crossover controlled clinical study of the treatment of Alport syndrome with Henagliflozin, Finerenone, and combination therapy. |
|
|
| Recruiting | 1 | 60 | | Henagliflozin: In the first cycle (from day 1 to day 60), patients assigned to the SGLT2i group were required to take the corresponding medication for one month (SGLT2i group: Henagliflozin 10mg qd + 1 tablet of Finerenone placebo), followed by one month of placebo washout (2 placebos, including 1 SGLT2 placebo + 1 MRA placebo). In the second cycle (from day 61 to day 120), the patients in this group were randomly divided into two subgroups, each receiving a different drug treatment from the first cycle (one subgroup received MRA + SGLT2i placebo, and the other subgroup received SGLT2i + MRA). In the third cycle (from day 121 to day 180): each group of patients received a different drug treatment plan from the first and second cycles for one month, followed by one month of placebo washout.; Finerenone: The first cycle (from day 1 to day 60) involved patients randomly assigned to the MRA group who were required to take the corresponding medication for one month (MRA group: Finerenone 10mg qd + 1 tablet of Henagliflozin placebo), followed by one month of placebo washout. In the second cycle (from day 61 to day 120), the patients in this group were randomly divided into two subgroups, each receiving a different drug treatment from the first cycle (one subgroup received SGLT2i + MRA placebo, and the other subgroup received SGLT2i + MRA). In the third cycle (from day 121 to day 180): each group of patients received a different drug treatment plan from the first and second cycles for one month, followed by one month of placebo washout; Henagliflozin+Finerenone: The first cycle (Day 1 to Day 60) involved the random allocation of patients to the combination therapy group, where they were required to take the corresponding medication for one month (combination therapy group: empagliflozin 10mg qd + finerenone 10mg qd), followed by one month of placebo. In the second cycle (Day 61 to Day 120), the patients in this group were randomly divided into two subgroups, each receiving a different drug regimen from the first cycle (one subgroup received SGLT2i + MRA placebo, and the other subgroup received SGLT2i placebo + MRA). The third cycle (Day 121 to Day 180) involved each group of patients receiving a different drug treatment plan from both the first and second cycles for one month, followed by one month of placebo washout. | peking university first hospital; peking university first hospital, Undertaking by the investigator | Alport syndrome | | | | |
